ArticleBone marrow transplantation2020
Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation.
Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin.Annals of hematology · 2021Trial
- Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation.Haematologica · 2026Article
- Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan.British journal of haematology · 2025Article
- [Chinese expert consensus on quality control, result analysis, and reporting of anti-HLA antibody testing in allogeneic hematopoietic stem cell transplantation (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- [Chinese expert consensus on the clinical interpretation of donor-specific anti-HLA antibody test results in HLA-mismatched hematopoietic stem cell transplantation (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Indirect presentation of mismatched human leukocyte antigen-B associates with outcomes of cord blood transplantation.British journal of haematology · 2025Article
- Review
- ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies.Transplantation and cellular therapy · 2024Review
- Desensitization Strategies for Donor-Specific Antibodies in HLA-Mismatched Stem Cell Transplantation Recipients: What We Know and What We Do Not Know.Oncology and therapy · 2024Review
- Development of an umbilical cord blood transplantation-specific nonrelapse mortality risk assessment score.Blood advances · 2024Article
- Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia.Blood cancer journal · 2022Article
- Recent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2022Review
- Umbilical cord blood transplantation: Still growing and improving.Stem cells translational medicine · 2021Review
- Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2021Article
- Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft failure (GF) remains a major complication of cord blood transplantation (CBT). Although the presence of pretransplant, donor-specific anti-HLA antibodies (DSA) was reported to be associated with an increased risk of GF after CBT, data are still limited. Thus, we conducted a retrospective analysis of recipients of single-unit CBT with pretransplant anti-HLA antibodies using the database of Japan Society for Hematopoietic Cell Transplantation (JSHCT). Data for recipients of single-unit CBT with pretransplant anti-HLA antibodies from 2010 to 2014 were obtained. In total, 343 patients who received CBT and who had detailed information about anti-HLA antibodies were included. The median age was 51 years (range, 0-71). Regarding DSA, 25 patients had a mean fluorescence intensity (MFI) ≥ 1000 (DSA-positive group) and 318 patients had a MFI <1000 (DSA-negative group). The cumulative incidence of neutrophil engraftment at 60 days after CBT was 75.7% (95% CI, 70.6-80.1) in the DSA-negative group and 56.0% (95% CI, 34.1-73.1) in the DSA-positive group (P = 0.03). In conclusion, pretransplant DSA with a MFI ≥ 1000 was associated with an increased risk of GF in single-unit CBT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.